64 completed, 10 terminated, 4 withdrawn, 2 unknown. 25 Phase 2, 24 Phase 3, 23 Phase 1, 5 Phase 4, 1 Not applicable.
Follow telaprevir: new trials by email Literature Review of telaprevir trials Research Report on telaprevir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions Telaprevir, Boceprevir, Sofosbuvir - Chronic Hepatitis C Infection | Completed | Valme University Hospital | 1128 | 2014-12-01 | 2022-06-29 | |
| Telaprevir in Genotype 3 HCV Telaprevir, 40 Kd Pegylated interferon alfa 2a, Ribavirin - Hepatitis C | Phase 4 | Completed | Queen Mary University of London | 14 | 2014-04-01 | 2023-01-05 |
| Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT) Ribavirin, Telaprevir - HIV | Phase 3 | Completed | St Stephens Aids Trust | 20 | 2014-01-01 | 2017-04-12 |
| Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1 Telaprevir and Sofosbuvir - Hepatitis C, Chronic | Phase 2 | Completed | University of Florida | 20 | 2013-12-01 | 2018-04-23 |
| Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1 Telaprevir, Peginterferon alfa-2a, Ribavirin - Hepatitis C | Phase 2 / Phase 3 | Withdrawn | Timothy Morgan, MD | 2013-08-01 | 2014-05-14 | |
| Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection Miravirsen, Telaprevir, Ribavirin - Hepatitis C, Chronic | Phase 2 | Unknown | Santaris Pharma A/S | 20 | 2013-06-01 | 2014-11-18 |
| A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults ABT-450/r/ABT-267, ABT-333, Ribavirin, Pegylated Interferon a-2a (PegINF) - Chronic Hepatitis C Infection | Phase 3 | Completed | AbbVie | 148 | 2013-06-01 | 2018-06-06 |
| Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients BI 201335, ribavirin, BI 207127 - Hepatitis C, Chronic | Phase 3 | Withdrawn | Boehringer Ingelheim | 2013-05-01 | 2014-01-23 | |
| Interaction Between Paroxetine and Telaprevir Paroxetine, telaprevir - Hepatitis C Infection, Depression | Phase 2 | Terminated | Radboud University Medical Center | 3 | 2013-05-01 | 2020-12-08 |
| Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC) Pegylated Interferon Alfa 2a, Ribavirin, Telaprevir - Infection | Phase 3 | Terminated | M.D. Anderson Cancer Center | 1 | 2013-04-01 | 2020-09-24 |
| Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers Telaprevir - Viral Hepatitis C | Phase 4 | Withdrawn | Massachusetts General Hospital | 2013-04-01 | 2014-08-13 | |
| A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before ABT-450/r/ABT-267, ABT-333, Ribavirin, Telaprevir - Chronic Hepatitis C Infection | Phase 3 | Completed | AbbVie | 311 | 2013-03-01 | 2018-06-06 |
| A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole PPI-668, Midazolam, Omeprazole - Pharmacokinetic Assessments in Healthy Volunteers | Phase 1 | Completed | Presidio Pharmaceuticals, Inc. | 24 | 2013-02-01 | 2013-03-26 |
| An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus Telaprevir, Peginterferon alfa-2b, Ribavirin - Hepatitis C | Phase 1 / Phase 2 | Terminated | Vertex Pharmaceuticals Incorporated | 42 | 2013-01-01 | 2016-07-20 |
| Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy Peginterferon Lambda-1a, Peginterferon Alfa-2a, Ribavirin - Hepatitis C | Phase 3 | Completed | Bristol-Myers Squibb | 444 | 2013-01-01 | 2015-10-09 |
| Viral Kinetics in HCV Clearance in Subjects With Hemophilia PegInterferon, Ribavirin, Telaprevir - Chronic Hepatitis C, Hemophilia | Phase 1 | Completed | Kenneth Sherman | 5 | 2012-12-01 | 2015-04-06 |
| Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C MBL-HCV1, Telaprevir (Part 1), Sofosbuvir (Part 2) - Hepatitis C Infection | Phase 2 | Terminated | MassBiologics | 11 | 2012-11-21 | 2021-02-05 |
| A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects Daclatasvir, Asunaprevir, Ribavirin - Hepatitis C Virus Infection | Phase 3 | Completed | Bristol-Myers Squibb | 258 | 2012-11-01 | 2015-10-09 |
| Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects Eltrombopag, Boceprevir, Telaprevir - Thrombocytopaenia | Phase 1 | Completed | GlaxoSmithKline | 56 | 2012-08-01 | 2017-11-13 |
| Dose Ranging of GSK2336805 in Combination Therapy GSK2336805 40 mg, GSK2336805 60 mg, Pegylated interferon alpha-2a - Hepatitis C, Chronic | Phase 2 | Completed | GlaxoSmithKline | 286 | 2012-08-01 | 2017-06-02 |
Showing 20 of 81. Sign in to see all of them.
Hepatitis C (54) · Hepatitis C, Chronic (29) · Infections (4) · Acquired Immunodeficiency Syndrome (3) · HIV Infections (3) · Fibrosis (2) · Thrombocytopenia (2) · Carcinoma, Hepatocellular (1) · Depression (1) · Hemophilia A (1) · Hepatic Insufficiency (1) · Hepatitis (1) · Kidney Diseases (1) · Liver Diseases (1) · Needlestick Injuries (1)
Vertex Pharmaceuticals Incorporated (22) · Tibotec BVBA (10) · Tanabe Pharma Corporation (6) · Janssen-Cilag International NV (5) · Bristol-Myers Squibb (4) · Janssen Infectious Diseases BVBA (4) · AbbVie (2) · GlaxoSmithKline (2) · Hoffmann-La Roche (2) · Santaris Pharma A/S (2) · Valme University Hospital (2) · ViiV Healthcare (2) · ANRS, Emerging Infectious Diseases (1) · Boehringer Ingelheim (1) · Eisai Inc. (1)
United States (42) · Germany (25) · France (19) · United Kingdom (19) · Spain (18) · Belgium (14) · Canada (13) · Puerto Rico (12) · Austria (11) · Poland (10) · Netherlands (9) · Australia (8) · Japan (8) · Brazil (7) · Israel (7)
Fumitaka Suzuki, MD (6) · Paul Rice, MD (2) · Alireza Manhuchehri (1) · Andrew H. Talal, MD, MPH (1) · David Burger, PharmD, PhD (1) · Graham R Foster (1)
PMID 22239511, PMID 26321288, PMID 30853642, PMID 37671831, PMID 19403902, PMID 19403903, PMID 20375406, PMID 21690488, PMID 21696307, PMID 21696308, PMID 21827730, PMID 21916639, PMID 22239508, PMID 22387529, PMID 23190247, PMID 23321318, PMID 23383655, PMID 23478952, PMID 23685940, PMID 23743475, PMID 24316262, PMID 24382638, PMID 24486089, PMID 24811404, PMID 24838177, PMID 24886541, PMID 24901821, PMID 24982088, PMID 25139963, PMID 25512630, PMID 25653396, PMID 25712364, PMID 25975423, PMID 25975934, PMID 26398503, PMID 26416471, PMID 26483516, PMID 26752189, PMID 27327078, PMID 27415157, PMID 27741230, PMID 27882706, PMID 28004322, PMID 28137633, PMID 28599618, PMID 29377515
2009 (1), R34HL109334 (1)